Puma Biotechnology Stock Performance
| PBYI Stock | USD 2.99 0.22 7.94% |
The company holds a Beta of -0.51, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Puma Biotechnology are expected to decrease at a much lower rate. During the bear market, Puma Biotechnology is likely to outperform the market. At this point, Puma Biotechnology has a negative expected return of -0.0317%. Please make sure to check Puma Biotechnology's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to decide if Puma Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Puma Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Puma Biotechnology is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return 19.73 | Five Day Return 22.6 | Year To Date Return 14.74 | Ten Year Return (98.33) | All Time Return (74.43) |
1 | New Strong Buy Stocks for December 24th | 12/24/2024 |
2 | Disposition of 33841 shares by Alan Auerbach of Puma Biotechnology at 3.1517 subject to Rule 16b-3 | 01/02/2025 |
3 | GSKs ADC Drug Gets FDAs Breakthrough Tag for Rare Bone Cancer | 01/07/2025 |
4 | SNYs Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study | 01/10/2025 |
5 | ALNY Announces Preliminary 2024 Results, 2025 View Pipeline Goals | 01/13/2025 |
6 | SNYs Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation | 01/14/2025 |
7 | Is Now The Time To Put Puma Biotechnology On Your Watchlist | 01/17/2025 |
8 | Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635 | 02/05/2025 |
9 | Acquisition by Alan Auerbach of 274622 shares of Puma Biotechnology at 2.78 subject to Rule 16b-3 | 02/07/2025 |
10 | Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results | 02/13/2025 |
11 | Puma Biotechnology to Present at TD Cowens 45th Annual Health Care Conference | 02/26/2025 |
| Begin Period Cash Flow | 86.7 M |
Puma |
Puma Biotechnology Relative Risk vs. Return Landscape
If you would invest 320.00 in Puma Biotechnology on December 1, 2024 and sell it today you would lose (21.00) from holding Puma Biotechnology or give up 6.56% of portfolio value over 90 days. Puma Biotechnology is currently does not generate positive expected returns and assumes 4.1641% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Puma, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Puma Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Puma Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Puma Biotechnology, and traders can use it to determine the average amount a Puma Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0076
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PBYI |
Estimated Market Risk
| 4.16 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Puma Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Puma Biotechnology by adding Puma Biotechnology to a well-diversified portfolio.
Puma Biotechnology Fundamentals Growth
Puma Stock prices reflect investors' perceptions of the future prospects and financial health of Puma Biotechnology, and Puma Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Puma Stock performance.
| Return On Equity | 0.49 | ||||
| Return On Asset | 0.0973 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 148.85 M | ||||
| Shares Outstanding | 49.09 M | ||||
| Price To Earning | 18.52 X | ||||
| Price To Book | 2.06 X | ||||
| Price To Sales | 0.76 X | ||||
| Revenue | 230.47 M | ||||
| Gross Profit | 166.1 M | ||||
| EBITDA | 30.97 M | ||||
| Net Income | 30.28 M | ||||
| Cash And Equivalents | 77.96 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 52.36 M | ||||
| Debt To Equity | 5.19 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | 1.45 X | ||||
| Cash Flow From Operations | 38.92 M | ||||
| Earnings Per Share | 0.62 X | ||||
| Market Capitalization | 175.73 M | ||||
| Total Asset | 213.33 M | ||||
| Retained Earnings | (1.31 B) | ||||
| Working Capital | 56.8 M | ||||
| Current Asset | 223.55 M | ||||
| Current Liabilities | 32.44 M | ||||
About Puma Biotechnology Performance
By evaluating Puma Biotechnology's fundamental ratios, stakeholders can gain valuable insights into Puma Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Puma Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Puma Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 49.44 | 52.91 | |
| Return On Tangible Assets | 0.19 | 0.20 | |
| Return On Capital Employed | 0.26 | 0.28 | |
| Return On Assets | 0.14 | 0.15 | |
| Return On Equity | 0.33 | 0.35 |
Things to note about Puma Biotechnology performance evaluation
Checking the ongoing alerts about Puma Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Puma Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Puma Biotechnology generated a negative expected return over the last 90 days | |
| Puma Biotechnology has high historical volatility and very poor performance | |
| Puma Biotechnology has a strong financial position based on the latest SEC filings | |
| About 60.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Puma Biotechnology to Present at TD Cowens 45th Annual Health Care Conference |
- Analyzing Puma Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Puma Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Puma Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Puma Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Puma Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Puma Biotechnology's stock. These opinions can provide insight into Puma Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |